PanGIA Biotech Announces Peer-Reviewed Study in Diagnostics Showing 97.8% Sensitivity in Detecting Prostate Cancer Using a Urine-Based Liquid Biopsy with Machine Learning
On April 2, 2026, in Delray Beach, Florida, PanGIA Biotech, Inc. unveiled significant findings from a peer-reviewed clinical study titled "Urine-Based Machine Learning Assay Detects Prostate Cancer" published in Diagnostics. The study showcased the clinical efficacy of PanGIA Analysis System (PAS) in detecting prostate cancer with remarkable accuracy. The research underscores the potential of PAS to revolutionize prostate cancer diagnosis and treatment.